It would be prudent to wait and examine the real-world impact of the IRA s drug-pricing provisions to ensure any legislation doesn t inadvertently affect innovation.
Republicans acknowledge there is no short-term legislative path to claw back or tweak the parameters of Medicare price negotiations but want a better understanding of how the CBO estimates the long-term effects of health care policy.
American families are sitting around the dining room table trying to figure out how to tighten their belts while the federal government looks for new ways to spend your tax dollars.
Medicare just announced the first 10 drugs that will be subject to government price limits under last year s Inflation Reduction Act (IRA). The list will be expanded each year and will eventually
America s life-science industry is braced for the impact of last year s Inflation Reduction Act, which will soon impose price caps on a range of popular drugs covered by Medicare.